About Us

Our Profile

Global Mind Screen Group Pty Ltd ("GMS") is a private mental health company whose business value to healthcare professionals is in providing solutions to help you help your mental health patients and more efficiently manage your practice. GMS’s value to mental health sufferers and the community as a whole is to deliver significantly improved mental health outcomes through what is a paradigm shift in the way mental health is assessed, and monitored and treatment is managed.

GMS's Mission is to be the world’s leading mental health assessment tool and information provider to practitioners, specialists, industry, governments and of course the public. GMS is currently expanding from Australia into New Zealand and the United States of America with more countries being rolled out in 2008. Become a GMS Partner in these countries and others around the world.

GMS is all about making a real and tangible difference to the many millions of everyday people impacted by mental health.

History

The Integrated Mind Institute Pty Ltd ("IMI") was incorporated in June 2003 to further develop and commercialise the intellectual property and core technology originally developed by Medivision International Pty Ltd, an Australian medical research and development company. The IM Screen software was developed in response to the worldwide mental health crisis and the need for significantly improved approaches to diagnosis, treatment and monitoring of patients. IM Screen v1.0 was developed as a traditional software delivered tool that was ‘loaded up’ at a limited number of medical centres.

In 2005 IMI partnered with Platform Interactive Pty Ltd, an Internet software development company, to web-enable the Mind Screen. This allowed IMI to regularly and instantly add new functionality to the IM Screen for accredited practitioners.

In 2006 and the first half of 2007 the IM Screen v2.1 was updated with significant backend functionality added to the product. Also in 2007 IMI began planning its entry into New Zealand and the United States.

In August 2007, IMI changed its name to Global Mind Screen Group Pty Ltd to better reflect its global vision and at the same time the IM Screen was renamed the Mind Screen.

In September 2007 Mind Screen v2.2 Beta was launched with a new Care Planning functionality that enables the doctor to access Medicare rebates.

Global Mind Screen is currently working on version 3.0 of the Mind Screen which will further improve practitioner work flow by becoming partially integrated into patient management software solutions.

Executive Profiles

Stephen Rice, Executive Chairman
Stephen has significant experience in commercializing emerging technologies. He is innovative and creative and the recipient of an Australian DesignMark Award for designing and developing an integrated range of business management software solutions. Stephen is the CEO of Plan Exit www.planexit.biz, a project development company and incubator of emerging technologies. He is the Chairman of Platform Interactive www.platforminteractive.com.au, an Internet software and web management systems company and holds board positions in other technology businesses. Stephen's expertise includes strategic management and corporate planning, commercialization of intellectual property and emerging technologies, as well as business systems and marketing.

Marshall Couper, Executive Director BCom (Hons) Econ
Marshall has served as a diplomat and trade negotiator in Geneva, Switzerland at the World Trade Organization, World Intellectual Property Organization, and United Nations Conference on Trade and Development. He was previously an Investment Manager with Prudential-Bache International (U.K.) Limited, has worked in the UK in venture capital and has consulted to major Australian companies in the area of performance improvement. Marshall has served on the board of Stirling Products Ltd (ASX:STI) and most recently was the CEO of Sun Biomedical Limited (formerly Harrington Group Limited) (ASX:SBN) a bio-technology company whose core business is commercializing world leading saliva screening devices for drugs of abuse.

Dr John Clarkson, Non-Executive Director MB CHB Dip.Obst FRACGP ADAPsych ACPsychMED
Dr John Clarkson’s medical career as a general practitioner, obstetrician, healthcare consultant and psychotherapist spans over thirty years. Today he works in private practice, consulting exclusively in the fields of Psychiatric (CNS) Disorders, Analytical Psychotherapy, and Psychological Medicine while pursuing his areas of interest, namely mood disorders and their co-morbid conditions, neuro-science and brain imaging (SPECT) and psychiatric diagnostic screening. As an entrepreneurial General Practitioner focused on the specialist area of mental health, John is regularly invited to present at conferences. Practitioners, professionals, and the medical industry enthusiastically receive his seminars and workshops on Psychiatric Disorders. He was granted a Fellowship to the newly formed Australian College of Psychological Medicine in 2003.

Dr Christopher C Green, Non-Executive Director MD, PhD, FAAFS
Dr Christopher (Kit) Green is in the practice of forensic medicine (Fellow, American Academy of Forensic Sciences) and neuro-imaging (Detroit Medical Centre/Harper University Hospital/Wayne School of Medicine). His work clinically relates to his expertise as a neurophysiologist with a specialty in electrophysiology. He is both a faculty member at the Medical School and Fellow in Diagnostic Radiology, and Executive Director for Emergent Technologies. He holds dual appointments in the Departments of Psychiatry & Behavioral Neurosciences and Diagnostic Radiology. Kit serves on numerous Department of Defence, Intelligence and National Academy of Sciences Commissions. He Chairs the Science Board for the Undersecretary of the Army for Operations Research, and has served as Chair of the Board on Army Science and Technology. He has operated a private forensic medical consulting company for 30 years specialising in investigations of unexplained death and disease, and injury related to biomechanics and exposures to threat agents.

He serves on the Boards of many development stage companies engaged in novel and advanced technologies, especially in the energy and environmental arena, especially in markets in Asia and the Middle East. He holds the National Intelligence Medal for investigations in forensic intelligence. He served as an Officer and continues as a consultant with the Central Intelligence Agency since 1969, and was Chief Technology Officer for General Motors Asia Pacific through 2004, prior to his return to full-time medical practice.